

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT — TOUMAI ORDERS EXCEEDING 100 UNITS WORLDWIDE

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis to provide the shareholders of the Company (the **“Shareholders”**) and potential investors the updates on the latest business development of the Group.

According to the preliminary internal statistics of the Group, as of the date of this announcement, the cumulative order volume of the Group's laparoscopic, orthopedic and vascular interventional core products has exceeded 170 units. Among them, the core product, Toumai Laparoscopic Surgical Robot (**“Toumai”**) has accumulated over 100 commercial orders worldwide, with installations worldwide nearly 80 units, firmly ranking first among domestic brands, and the commercialisation process has entered into a phase of full-scale acceleration.

Leveraging the Group's pioneering innovation ecosystem integrating robotics and remote technology, Toumai is accelerating its fulfilment of multi-level clinical demands across global markets. As of the date of this announcement, the number of human clinical surgeries performed by Toumai worldwide has accumulatively exceeded 15,000 cases.

As the first domestic laparoscopic surgical robot to enter the overseas market, Toumai has received over 60 orders overseas, with installations covering nearly 40 countries and regions across Asia, Europe, Africa, Oceania and South America. Toumai has also been installed in mainstream hospital systems in dozens of countries including Italy, Belgium, India, Brazil, Argentina and the United Arab Emirates, and has been used for large-scale clinical surgeries. Recently, the Group's commercialisation layout in the global high-end medical market has ushered in another milestone breakthrough. Toumai has completed the commercial deployment of single-port and multi-port series at one of the top two leading medical institutions in the world, successfully implementing the combined comprehensive intelligent surgical solution.

The board of directors of the Company wishes to remind the Shareholders and potential investors of the Company that the above information is unaudited and is based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 8 October 2025

As at the date of this announcement, the executive directors of the Company are Dr. He Chao, Mr. Liu Yu and Ms. Fang Cong, the non-executive directors of the Company are Mr. Sun Hongbin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.